Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 51 - 60 of 60

Selected Filters:
9 August 2022

AIDSVu

AIDSVu is an interactive online mapping tool that visualizes the impact of the HIV epidemic on communities across the United States to increase disease awareness and promote data-driven public health decision-making. This includes information on PrEP use and need from national to city level.

Monitoring & Evaluation

External Link
1 August 2022

USA HIV National Strategic Plan A Roadmap to End the Epidemic, 2021-25

This HIV National Strategic Plan (HIV Plan) sets forth bold targets for ending the HIV epidemic in the United States by 2030. The HIV Plan articulates goals, objectives and strategies to prevent new infections, treat people with HIV to improve health outcomes, reduce HIV-related disparities, and better integrate and coordinate the efforts of all partners…

Normative Guidance/Policies

Document
7 July 2022

DISCOVER study for HIV pre-exposure prophylaxis (PrEP): F/TAF has a more rapid onset and longer sustained duration of HIV protection compared with F/TDF

In the DISCOVER study, F/TAF oral PrEP (Descovy) was statistically noninferior to F/TDF oral PrEP (Truvada). However, there were numerically 53% fewer HIV infections in the F/TAF arm vs. F/TDF . This study explores HIV risk, STIs, adherence, and pharmacokinetic data to evaluate this imbalance.

Research

External Link
7 July 2022

DISCOVER Trial Factsheet

This factsheet provides details on the DISCOVER trial to assess whether F/TAF (trade name Descovy) is as safe and effective as an oral daily HIV pre-exposure prophylaxis (PrEP) product.

Community/Advocacy, Research

External Link
7 July 2022

Descovy for PrEP

The U.S. Food and Drug Administration has reported that they have approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) who at at risk of acquiring HIV.

Normative Guidance/Policies

External Link
7 July 2022

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic

This article announces the U.S. Food and Drug Administration's approval of Descovy in at-risk adults and adolescents for HIV pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection from sex, excluding those who have receptive vaginal sex.

Normative Guidance/Policies

External Link
7 July 2022

Descovy for PrEP – FDA Supplemental Approval

This letter from the US Food and Drug Administration outlines supplemental approval granted to Descovy, an oral PrEP medication.

Normative Guidance/Policies

External Link
24 July 2020

Guidance for the Use of Pre-exposure Prophylaxis (PrEP) for the Prevention of HIV Acquisition in British Columbia

These guidelines were developed by the British Columbia Centre for Excellence in HIV/AIDS and focus on the provision of PrEP as a part of a comprehensive approach to combination prevention, drawing on implementation and research evidence and WHO recommendations.

Normative Guidance/Policies

Document
17 December 2018

PrEP for the Prevention of HIV Infection of HIV Infection in the United States – 2017 Update

Preexposure Prophylaxis for HIV Prevention in the United States – 2017 Update: A Clinical Practice Guideline provides comprehensive information for the use of daily oral antiretroviral preexposure prophylaxis (PrEP) to reduce the risk of acquiring HIV infection in adults.

Normative Guidance/Policies

Document
17 December 2018

National HIV/AIDS Strategy for the United States (2015 – 2020)

The nation’s comprehensive strategy for HIV/AIDS prevention and treatment.

Normative Guidance/Policies

Document